Bristol Myers Squibb Company (BMY) vs Grifols, S.A. (GRFS)
- Bristol Myers Squibb Company BMY 59.71 −1.42%
- Grifols, S.A. GRFS 7.64 +1.33%
Bristol Myers Squibb Company and Grifols, S.A. are both Drug Manufacturers General companies. Bristol Myers Squibb Company is the larger, with a market value of $123.7B against $2.0B — 63.5× the size. Grifols, S.A. trades at the lower P/E: 8.5× against 13.2×. Grifols, S.A. grew revenue faster over the last twelve months: 16.0% against 3.11%. Bristol Myers Squibb Company has the higher net margin (18.9% vs 5.54%) and the higher return on invested capital (13.7% vs 0.00%). Both pay a dividend; Bristol Myers Squibb Company yields more (4.22% vs 1.24%). Across the 23 metrics below, Grifols, S.A. leads on 12 and Bristol Myers Squibb Company on 11.
Valuation
Profitability
| Metric | BMY | GRFS | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 70.16% | 37.45% | 72.77% |
| Operating margin | 24.22% | 16.43% | 18.77% |
| Net margin | 18.87% | 5.54% | 8.27% |
| Free cash flow margin | 23.26% | 0.00% | 17.18% |
| Return on equity | 46.63% | 0.00% | 5.87% |
| Return on assets | 10.18% | 0.00% | 2.57% |
| Return on invested capital | 13.69% | 0.00% | 6.11% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack